NCT01854593.

Trial name or title	Prospective randomized controlled study on the efficacy of 0.16 mg intravitreal bevacizumab injection for proliferative diabetic retinopathy
Methods	Randomised, double‐masked, controlled trial
Participants	66 (recruitment completed August 2013)
Interventions	Control group: sham injection and 25 gauge vitrectomy Intervention group: 0.16 mg/0.05 ml bevacizumab (single injection 1 day before operation) and 25 gauge vitrectomy
Outcomes	VEGF concentration in vitreous after intravitreal bevacizumab injection [ Time Frame: 1 year ] Early (within 4 weeks) postoperative vitreous haemorrhage Re‐operation due to vitreous haemorrhage
Starting date	May 2012
Contact information	Ayumu Manabe, Nihon University
Notes	Study results on ClinicalTrials.gov

BCVA: Best‐corrected visual acuity
 ETDRS: Early Treatment Diabetic Retinopathy Study
 PDR: proliferative diabetic retinopathy
 TRD: tractional retinal detachment
 VEGF: vascular endothelial growth factor